Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| 45.01 | |
| 44.56 | |
| - | |
| 45.42 | |
| 44.5 | |
| 25.58-62.4 | |
| 8 580 M | |
| 185 M | |
| 742 K | |
| -0.94 | |
| 1.404 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Revolution Medicines, Inc. Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be fe...
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks.In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands agains...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
